PA
ITOS

Perceptive Advisors’s iTeos Therapeutics ITOS Stock Holding History

Perceptive Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$931K – 144
2021
Q4 		$931K Buy
+20,000
New +$666K 0.01% 137

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Perceptive Advisors's ITOS Position: Q1 2022 in Review

Perceptive Advisors sold out of iTeos Therapeutics (ITOS) in Q1 2022, closing a stake of 20,000 shares — an estimated $931K sold.

Perceptive Advisors first reported a position in ITOS in Q4 2021 and held it in 1 quarter. The position peaked at $931K in Q4 2021. 159 funds tracked by Wall St. Rank hold ITOS as of Q1 2022.

  • Perceptive Advisors reported no remaining iTeos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 20,000 iTeos Therapeutics shares in Q1 2022, an estimated $931K.
  • Perceptive Advisors first reported a position in iTeos Therapeutics in Q4 2021 and held it in 1 quarter.
  • Perceptive Advisors's iTeos Therapeutics position peaked at $931K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.